About CDT Equity Inc.
https://www.conduitpharma.comCDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.
CEO
Andrew Regan
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public March 28, 2022
Full time employees 6
Ratings Snapshot
Rating : B-
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 2
Price To Earnings 1
Price To Book 4
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $12221
52w High $0.01
52w Low $0.01
P/E 0
Volume 17.50K
Outstanding Shares 1.63M
About CDT Equity Inc.
https://www.conduitpharma.comCDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $6.15M ▲ | $-7.12M ▼ | 0% | $4.05 ▲ | $-6.28M ▼ |
| Q2-2025 | $0 | $4.95M ▲ | $-6.03M ▼ | 0% | $1.54 ▲ | $-5.14M ▼ |
| Q1-2025 | $0 | $3.62M ▲ | $-4.75M ▼ | 0% | $-1.32 ▼ | $-4.38M ▼ |
| Q4-2024 | $0 | $3.06M ▼ | $-2.41M ▲ | 0% | $3.88 ▲ | $-994K ▲ |
| Q3-2024 | $0 | $5.81M | $-6.46M | 0% | $1.32 | $-6.15M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.83M ▲ | $8.55M ▲ | $4.27M ▼ | $4.28M ▲ |
| Q2-2025 | $3.33M ▲ | $7.99M ▲ | $4.46M ▼ | $3.53M ▲ |
| Q1-2025 | $2.13M ▼ | $7.32M ▲ | $4.63M ▼ | $2.69M ▲ |
| Q4-2024 | $370.3M ▲ | $4.19M ▲ | $10.99M ▼ | $-6.79M ▲ |
| Q3-2024 | $152K | $2.99M | $12.11M | $-9.12M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $56.69M ▲ | $105.01M ▲ | $-39.8M ▼ | $-54.16M ▼ | $12.77M ▲ | $65.33M ▲ |
| Q2-2025 | $-6.03M ▼ | $-2.58M ▼ | $-1K ▲ | $3.76M ▲ | $1.2M ▲ | $-2.58M ▲ |
| Q1-2025 | $51.94M ▲ | $7.44M ▲ | $-24.18M ▼ | $-96.78M ▼ | $-111.31M ▼ | $-24.76M ▼ |
| Q4-2024 | $-2.41M ▲ | $-3.81M ▼ | $85K ▼ | $4.21M ▲ | $483K ▲ | $-3.81M ▼ |
| Q3-2024 | $-6.46M | $-2M | $96K | $1.74M | $-148K | $-2.04M |
CEO
Andrew Regan
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public March 28, 2022
Full time employees 6
Ratings Snapshot
Rating : B-
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 2
Price To Earnings 1
Price To Book 4
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0